XGN Exagen

Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

CARLSBAD, Calif., March 08, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum, which takes place virtually March 19-20, 2024. John Aballi, Exagen’s President and Chief Executive Officer, and Kamal Adawi, Exagen’s Chief Financial Officer, will participate in one-on-one meetings with investors and a fireside chat on Wednesday, March 20, at 1:30 PM ET.

About Exagen Inc.

Exagen is a leading provider of autoimmune testing and its purpose as an organization is to provide clarity in autoimmune disease decision making with the goal of improving patients’ clinical outcomes. Exagen is located in San Diego County, California.

For more information, please visit or follow on X (formerly known as Twitter).

Contact:

Ryan Douglas

Exagen Inc.



760.560.1525



EN
08/03/2024

Underlying

XGNExagen

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Exagen

 PRESS RELEASE
Free
XGN EXAGEN

Exagen Inc. Reports Strong Q3 2025 Results

Exagen Inc. Reports Strong Q3 2025 Results CARLSBAD, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2025, and recent corporate updates.   Three Months Ended September 30, Nine Months Ended September 30,  2025 2024 2025 2024(Unaudited, in thousands, except ASP data)  Revenue $17,244  $12,507  $49,944  $41,986 Gross margin  58.4%  55.8%  59.3%  58.7%Operating expenses $13,175  $11,644  $38,688  $34,888 Operating loss $(3,100) $(4,663) $(9,095) $(10,2...

November 4, 2025 1 EN
 PRESS RELEASE
Free
XGN EXAGEN

Exagen Announces Acceptance of Six Abstracts at 2025 American College ...

Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence CARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of six abstracts at the 2025 American College of Rheumatology’s (ACR) annual meeting, ACR Convergence 2025, being held October 24-29, 2025, at the McCormick Place Convention Center in Chicago, Illinois. Exagen’s featured plenary presentation, in collaboration with Johns Hopkins University, will highlight a urinary biomarker panel that holds t...

October 23, 2025 1 EN
 PRESS RELEASE
Free
XGN EXAGEN

Exagen Inc. to Announce Third Quarter 2025 Financial Results on Novemb...

Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025 CARLSBAD, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended September 30, 2025, before the market opens on Tuesday, November 4, 2025. John Aballi, Exagen’s President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company’s results at 8:30 a.m. ET (5:30 a.m. PT). Conference Call & Webcast: U.S. dial-in: 201-389-0918Intern...

October 21, 2025 1 EN
 PRESS RELEASE
Free
XGN EXAGEN

Exagen Inc. to Participate in Third Quarter Investor Conferences

Exagen Inc. to Participate in Third Quarter Investor Conferences CARLSBAD, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, today announced that management will participate in the following upcoming investor conferences: Canaccord Genuity 45th Annual Growth Conference Participation: Fireside Chat and 1X1 Meetings Date: Tuesday, August 12, 2025 Location: InterContinental Hotel in Boston, MA Cantor Global Healthcare Conference 2025 Participation: Fireside Chat and 1X1 Meetings Date: W...

August 6, 2025 1 EN
 PRESS RELEASE
Free
XGN EXAGEN

Exagen Inc. Reports Strong Q2 2025 Results

Exagen Inc. Reports Strong Q2 2025 Results CARLSBAD, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2025, and recent corporate updates.   Three Months Ended June 30, Six Months Ended June 30,   2025   2024   2025   2024 (Unaudited, in thousands, exceptASP data)  Revenue $17,202  $15,064  $32,700  $29,479 Gross margin  60.4%  60.1%  59.7%  59.9%Operating expenses $13,025  $11,643  $25,513  $23,244 Operating loss $(2,630)  $(2,587)  $(5,995)  $(5,590) Net...

July 29, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch